Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Neoplasms 7Prostatic Neoplasms 5Brain Neoplasms 5Carcinoma, Non-Small-Cell Lung 3Radiation Injuries 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasm Metastasis 2Multiple Myeloma 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hemangioma 2Breast Neoplasms 2Urogenital Neoplasms 1Scleroderma, Localized 1Respiratory Distress Syndrome 1Radiation Pneumonitis 1Popliteal Cyst 1Polycystic Ovary Syndrome 1Pneumonia, Viral 1Pneumonia 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Optic Neuritis 1Neurodermatitis 1Neoplastic Cells, Circulating 1Neoplasms, Fibrous Tissue 1Neoplasms, Connective and Soft Tissue 1Neoplasms, Connective Tissue 1Neoplasms by Histologic Type 1Neoplasm, Residual 1Nasopharyngeal Carcinoma 1

Interventions

Cyclophosphamide 23blinatumomab 18Cytarabine 16fludarabine 13Azacitidine 12venetoclax 10fludarabine phosphate 10Rituximab 8Blood Specimen Collection 8Methotrexate 7Lenalidomide 7Dexamethasone 7Daunorubicin 7Mercaptopurine 6Vincristine 5daratumumab 4Whole-Body Irradiation 4Melphalan 4Idarubicin 4Etoposide 4Drug Therapy 4Busulfan 4pembrolizumab 3obinutuzumab 3Radiotherapy 3Neoadjuvant Therapy 3Maintenance 3Liquid Biopsy 3Immunotherapy, Adoptive 3Imatinib Mesylate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm, Residual × Adrenal Cortex Hormones × Clear all
NCT01059786 2025-06-12

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
69 enrolled 12 charts
Other hematologic neoplasm

Leukemia, Hairy Cell, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡